Recruiting
Phase 1
Phase 2

Radiation, Flt3L/CDX-301, Poly-ICLC, Pembrolizumab

Sponsor:

Icahn School of Medicine at Mount Sinai

Code:

NCT03789097

Conditions

Non-Hodgkin's Lymphoma

Metastatic Breast Cancer

Head and Neck Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Flt3L

Radiation

Poly ICLC

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-05. This information was provided to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai on 2024-01-30.